An attempt was made to explain the puzzling observation that in bacteria 2, 6-diaminopurine can replace guanine for guanineless mutants and for xanthineless mutants (both of which can make adenosine monophosphate de novo) but not for nonexacting purine auxotrophs (which cannot make adenosine monophosphate de novo). The analogue failed to inhibit the growth of nonexacting purineless Bacillus subtilis MB-1356 growing on guanine. In fact, growth was somewhat stimulated. This eliminated a possible solution involving the inhibition of guanosine monophosphate reductase by a diaminopurine derivative. Sparing of guanine by diaminopurine was matched by an even greater sparing of adenine. Addition of a small amount of adenine to MB-1356 failed to allow unrestricted growth on diaminopurine, thus eliminating a possible solution requiring an adenine derivative for the initial deamination of diaminopurine to guanine. The same degree of sparing of adenine by diaminopurine was observed whether both purines were added together or whether the adenine was added 1 hr after diaminopurine. This eliminated the possibility that diaminopurine was wasted by a "dead-end" conversion in the absence of adenine. Consideration of these nutritional data led to the development of two additional explanations, which are examined by tracer methodology in the following paper.
2, 6-Diaminopurine is an interesting synthetic compound which exhibits antipurine activity and growth factor activity in different organisms. Despite the fact that it was the first purine antimetabolite active against experimental tumors (17) , neither its growth-inhibitory nor its growthpromoting activity is completely understood on the molecular level (4) .
Studies on the utilization of diaminopurine by purine auxotrophs of Escherichia coli (2), Bacillus subtilis (10), Aerobacter aerogenes (5) , and Salmonella typhimurium (13) have revealed a puzzling situation. Specific adenineless mutants blocked at step I in Fig. 1 did not use diaminopurine as a replacement for adenine. Thus, it is clear that diaminopurine is not a direct precursor of an adenine compound. Xanthineless and guanineless auxotrophs, which were blocked at steps 2 and 3, respectively, and thus could make adenosine-5'-monophosphate (AMP) by de novo synthesis, did grow on diaminopurine which served as a source of a guanine compound. On the other hand, nonexacting purineless auxotrophs, blocked at step 4 and capable of using adenine, hypoxanthine, xanthine, or guanine, could not grow on diaminopurine. Thus, a paradoxical situation exists in bacteria. Diaminopurine can serve as a source of guanine, guanine can serve as a source of adenine, but diaminopurine does not appear to be a precursor of adenine. To solve this nutritional riddle, we examined the growth of various B. subtilis mutants on diaminopurine and on natural purines. The accompanying paper (21) , reports studies on the incorporation of radioactive purines by these same mutants.
MATERIALS AND METHODS
Organisms. B. subtilis MB-1356 is a nonexacting purineless mutant of the Marburg strain of B. subtilis (ATCC 6051). This organism grew in the basal medium when supplemented with guanine, guanosine, guanosine-5'-monophosphate (GMP), adenine, adenosine, adenosine monophosphate (AMP), hypoxanthine, inosine, inosine-5'-monophosphate (IMP), or xanthine, but it failed to grow with xanthosine or diaminopurine. Growth yields after overnight incubation and exponential rates of growth were similar witb all active purine sources, with the exception of 56 Growth measurements. AU experiments were done at 37 C by use of rotary shaking machines. Growth was measured by absorbance at 660 mu in the Bausch and Lomb Spectronic-20 colorimeter (Bausch and Lomb, Inc., Rochester, N.Y.) using tubes with an inside diameter of 11.7 mm or in a Klett-Summerson colorimeter using a no. 66 filter. Viable counts were done by the pour plate technique, dilutions being made in the mineral salts mixture of the basal medium. One Klett unit corresponded to a viable count of 3.7 X 106 cells/ml. Penassay agar (Difco) was used for the plates, and colonies were counted on triplicate plates after 1 day of incubation at 37 C.
RESULTS
Lack of inhibition by diaminopurine of growth in guanine or adenine. A summary of the nutritional responses of various B. subtilis strains is shown in Table 1 . One possibile explanation for the observed lack of growth of the nonexacting purine auxotroph MB-1356 on diaminopurine is that the analogue or a derivative, such as diaminopurine ribonucleoside triphosphate, inhibits GMP reductase. This enzyme converts GMP to IMP and thus is essential for the GMP AMP interconversion pathway. If such an inhibition occurred, diaminopurine could be converted to guanine but not to adenine; the synthetic purine could then only satisfy the growth requirement of guanine and of xanthine auxotrophs but could not satisfy the growth requirement of nonexacting mutants. As a basis for this hypothesis, the following may be considered: (i) the known inhibition of GMP reductase by adenosine triphosphate (ATP) (16); (ii) the ability of microorganisms to convert diaminopurine to its ribonucleoside triphosphate derivative (15, 20) ; and (iii) the replacement of ATP by diaminopurine ribonucleoside triphosphate in certain enzymatic reactions (15) .
If the above hypothesis is correct, the addition of diaminopurine to nonexacting cells growing on guanine should lead to an inhibition of growth owing to a resulting deficiency of AMP. This was tested by growing B. subtilis MB-1356 on guanine until the culture was in the log phase of growth. At this time, the culture was diluted with an equal volume of fresh medium containing guanine or with guanine plus a large excess of diaminopurine. The results (Fig. 2) show that log-phase cells were uninhibited by diaminopurine. In fact, a slight increase in growth rate was noted.
A second experiment was done to encourage any possible inhibitory effect of diaminopurine. In this experiment, addition of the synthetic purine was made toward the end of the exponential phase when guanine was practically depleted. (Fig. 4) . With these mutants, in which AMP is made by de novo synthesis, diaminopurine addition resulted in continued exponential growth.
Inability of adenine and guanine to permit unrestricted usage ofdiaminopurine. For diaminopurine to be a precursor of guanine, a deamination must take place at carbon 6, either at the level of a free base, a ribonucleoside, or a ribonucleotide. An analogous reaction is the deamination of adenine compounds to hypoxanthine derivatives. Specific enzymes have been described which act on adenine, adenosine, AMP, and adenosine diphosphate (ADP). Since adenase also converts diaminopurine to guanine (12) and adenosine deaminase also deaminates diaminopurine ribonucleoside (6), it is reasonable to assume that deamination of diaminopurine compounds in the cell is carried out by one or more of these enzymes. In the case of AMP deaminase, the enzyme is dependent upon ATP (18, 19) . If such a dependency exists for the conversion of a diaminopurine derivative to a guanine compound, then ATP would be required for growth of nonexacting purineless mutants on diaminopurine. If this hypothesis is correct, Fig. 3 Amole of guanine, 0.05 ,umole of diaminopurine was active, but further increases in diaminopurine had no effect. This indicates that the inability of diaminopurine alone to support growth of MB-1356 cannot be due to a requirement of an adenine compound for deamination.
Time of adenine addition to diaminopurine. If diaminopurine undergoes a reaction in addition to deamination to guanine, it is possible that such a conversion would represent a "dead end" as far as utilization is concerned. For example, E. coli methylates diaminopurine at the 2-amino position (20) . If AMP could prevent such a wasteful reaction, then cultures with large pools of AMP (e.g., xanthineless and guanineless mutants) would have more diaminopurine available for deamination to guanine. On the other hand, nonexacting purineless mutants would not be able to prevent the conversion since they cannot make AMP by de novo synthesis. If such a mechanism exists, the increased growth, resulting from the sparing adenine by diaminopurine, should be diminished when adenine is added 60 min after diaminopurine rather than adding both at zero-time. This decreased amount of growth would be the result of wasteful conversion of the synthetic purine to a nonutilizable form during the 60 min of preincubation in the absence of exogenous adenine.
To test the hypothesis, B. subtilis MB-1356 was grown with adenine until the culture was well into the exponential growth phase. Such cells (after washing) were incubated in basal medium with or without diaminopurine. To one tube of each series, adenine was added at 0 min, and to the other tube adenine was added at 60 min. Fig. 6 shows that the sparing effect of diaminopurine was of the same degree, irrespective of the time of adenine addition. Thus, the inactivity of diaminopurine cannot be ascribed to a "deadend" conversion of the synthetic purine in the absence of adenine. Viability studies. Although no evidence was obtained indicating a lytic effect of diaminopurine on the nonexacting purine auxotroph, it was of interest to determine whether B. subtilis MB-1356 was killed by diaminopurine in the absence of natural purines. As a control, guanineless B. subtilis MB-1517 was also studied. Overnight cultures, grown with GMP, were washed and incubated in basal medium with and without diaminopurine. The results in Table 2 show that diaminopurine was not bactericidal. The slight amount of growth observed with both cultures in the absence of diaminopurine is evidently the result of internal carryover of GMP in the inoculum. The limited increased growth of MB-1356 in diaminopurine can be ascribed to sparing of this guanine source. As expected, only MB-1517 showed good growth on diaminopurine.
DIscussIoN
In organisms which do not interconvert the purine nucleotides AMP and GMP, such as a Both cultures were grown overnight at 37 C in tubes containing GMP at 0.07 ,umole per ml. The cells were washed once with basal medium and were made up at their original concentration in basal medium. One ml of cells was added to 40 ml of basal medium, with and without 0.03 /umole of diaminopurine per ml. Incubation was carried out in a water-bath shaker at 37 C. man (11), rats, mice, hamsters (2, 3), yeast (14) , and Ophiostoma (9), diaminopurine was found to serve only as a source of nucleic acid guanine. This conversion of diaminopurine to guanine, regardless of whether the deamination occurred on the level of a free base, a ribonucleoside, or a ribonucleotide, is sufficient to explain the efficient use of diaminopurine by xanthineless and guanineless auxotrophs of microorganisms. Since guanine satisfies the growth requirement of nonexacting purine auxotrophs, the inability of diaminopurine to do so is an intriguing problem.
The present nutritional experiments eliminate the following possibilities as solutions of this dilemma: (i) inhibition of GMP reductase by a diaminopurine derivative; (ii) requirement of an adenine derivative for the deamination reaction; and (iii) a "dead-end" conversion of diaminopurine to a nonutilizable derivative, the reaction being reversed by adenine compounds. Figures 2, 3 , and 5 demonstrate that diaminopurine spares adenine and guanine. Such sparing activity has been reported for Lactobacillus casei (1), S. typhimurium (13) , and A. aerogenes (5). However, the comparative effect on adenine versus guanine utilization has not been reported previously. The data of Fig. 3 and 5 indicate a much greater sparing of adenine than of guanine. The ability of B. subtilis MB-1356 to use as much as 3 moles of diaminopurine per mole of adenine supplied (Fig. 5 ) certainly suggests that, to a limited degree, diaminopurine must be capable of supplying both guanine and adenine. The inability of diaminopurine to support any growth of MB-1356 in the absence of natural purines or to support extensive growth in the presence of a small amount of natural purine could be due to production of an inhibitor from diaminopurine, the formation or action of which is prevented by natural purines. The more extensive usage of diaminopurine in the presence of adenine than in the presence of guanine could mean that an adenine compound is the true competitor of the formation or action of the inhibitory analogue, guanine being active only to the extent of its conversion to an adenine derivative. This possibility, which is examined by tracer methodology in another study (21) , can be formulated as follows. Diaminopurine would undergo, in addition to the deamination reaction, conversion to an inhibitory form, such as diaminopurine ribonucleoside-5'-monophosphate or a coenzyme analogue derived from this nucleotide (4), and AMP would either repress formation of the inhibitor or reverse its inhibitory activity. Thus, xanthineless and guanineless mutants, which can make AMP by de novo synthesis, would not be inhibited and could use diaminopurine. Nonexacting mutants, on the other hand, would be inhibited when incubated with diaminopurine alone. When adenine (or guanine as a source of adenine) is also present, diaminopurine could be used but only until adenine was depleted; then inhibition would set in.
A second possibility remaining to be examined is that deamination of diaminopurine to guanine occurs at the level of the ribonucleotide di-or triphosphate and thus bypasses the GMP -* AMP interconversion pathway. This solution is less likely, however, since it does not account for the greater sparing of adenine than of guanine by diaminopurine.
